Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Sorafenib endometrial carcinoma not applicable detail...
FGFR2 N549K FIIN-1 endometrial carcinoma sensitive detail...
FGFR2 K310R FGFR2 N549K FIIN-1 endometrial carcinoma sensitive detail...
FGFR2 wild-type FIIN-1 endometrial carcinoma resistant detail...
Unknown unknown XL147 endometrial carcinoma not applicable detail...
FGFR2 S252W RO4987655 endometrial carcinoma decreased response detail...
FGFR2 N549K RO4987655 endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K RO4987655 endometrial carcinoma no benefit detail...
FGFR2 N549K RO5126766 endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K RO5126766 endometrial carcinoma no benefit detail...
FGFR2 S252W Selumetinib endometrial carcinoma decreased response detail...
FGFR2 N549K Selumetinib endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K Selumetinib endometrial carcinoma no benefit detail...
FGFR2 S252W RO5126766 endometrial carcinoma sensitive detail...
FGFR2 S252W GSK3052230 endometrial carcinoma sensitive detail...
MLH1 mutant N/A endometrial carcinoma not applicable detail...
MSH6 mutant N/A endometrial carcinoma not applicable detail...
Unknown unknown Lenvatinib + Pembrolizumab endometrial carcinoma not applicable detail...
PIK3CA mutant Copanlisib endometrial carcinoma no benefit detail...
Unknown unknown CC-90010 endometrial carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00492778 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01440998 Phase I Carboplatin + Dasatinib + Paclitaxel Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed
NCT01504126 Phase I Propranolol Beta-Blocker / Ovarian Completed
NCT01888562 Phase I Ponatinib Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Withdrawn
NCT01935973 Phase II Trametinib Trametinib + Uprosertib Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting
NCT02059265 Phase II Dasatinib Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting
NCT02065687 Phase III Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting
NCT02117817 Phase I Buparlisib + Nab-paclitaxel Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Withdrawn
NCT02228681 Phase II Tamoxifen Medroxyprogesterone Everolimus + Letrozole Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer Active, not recruiting
NCT02397083 Phase II Everolimus Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer Recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02549209 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembro/Carbo/Taxol in Endometrial Cancer Recruiting
NCT02549989 Phase II LY3023414 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Active, not recruiting
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Terminated
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT02725268 Phase II Paclitaxel Sapanisertib MLN1117 + Sapanisertib Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer Active, not recruiting
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed
NCT03008408 Phase II Everolimus + Letrozole + Ribociclib Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer Recruiting
NCT03015129 Phase II Durvalumab Durvalumab + Tremelimumab A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Active, not recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status
NCT03077698 Phase II Megestrol acetate + Sodium cridanimod An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer Completed
NCT03138408 Phase I SC-004 ABBV-181 + SC-004 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers Terminated
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03367741 Phase II Cabozantinib + Nivolumab Nivolumab Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Suspended
NCT03476798 Phase II Bevacizumab + Rucaparib Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Active, not recruiting
NCT03517449 Phase III Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Active, not recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03526432 Phase II Atezolizumab + Bevacizumab Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer Recruiting
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Suspended
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03836157 Phase II Bevacizumab + Mirvetuximab Soravtansine Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Withdrawn
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03884101 Phase III Carboplatin + Paclitaxel Lenvatinib + Pembrolizumab Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Recruiting
NCT03909152 Phase II Onapristone A Study of Onapristone ER in Gynecologic Cancers That Respond to Progesterone Recruiting
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Suspended
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting
NCT03932409 Phase I Pembrolizumab Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) Recruiting
NCT03955978 Phase I Dostarlimab TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer Recruiting
NCT04106414 Phase II Nivolumab BMS-986205 + Nivolumab Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Recruiting
NCT04205630 Phase II Trastuzumab Duocarmazine SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Recruiting
NCT04251416 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma Recruiting
NCT04269200 Phase III Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) Recruiting
NCT04469764 Phase II Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Not yet recruiting